{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:37:07Z","timestamp":1787499427577,"version":"build-2736575974"},"reference-count":119,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["mcpiqojournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.mayocpiqo.2022.09.002","type":"journal-article","created":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T20:18:13Z","timestamp":1665778693000},"page":"536-551","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus"],"prefix":"10.1016","volume":"6","author":[{"given":"Jay B.","family":"Wish","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Pergola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib1","series-title":"IDF Diabetes Atlas","year":"2019"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib2","unstructured":"Amorim RG, Guedes GDS, Vasconcelos SML, Santos JCF. Kidney disease in diabetes mellitus: cross-linking between hyperglycemia, redox imbalance and inflammation. Arq Bras Cardiol. 2019;112(5):577-587. Published correction appears in 2019;113(1):182."},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s13167-010-0004-7","article-title":"Inflammatory cytokines as predictive markers for early detection and progression of diabetic nephropathy","volume":"1","author":"Elmarakby","year":"2010","journal-title":"EPMA J"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2022.09.002_bib4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/(SICI)1096-9136(199604)13:4<313::AID-DIA56>3.0.CO;2-7","article-title":"Central role of TGF-beta in the pathogenesis of diabetic nephropathy and macrovascular complications: a hypothesis","volume":"13","author":"Yokoyama","year":"1996","journal-title":"Diabet Med"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib5","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.ajkd.2012.07.005","article-title":"KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update","volume":"60","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2019.107840","article-title":"IDF Diabetes Atlas: a review of studies utilising retinal photography on the global prevalence of diabetes related retinopathy between 2015 and 2018","volume":"157","author":"Thomas","year":"2019","journal-title":"Diabetes Res Clin Pract"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib9","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jchf.2014.08.004","article-title":"Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure","volume":"3","author":"Dei Cas","year":"2015","journal-title":"JACC Heart Fail"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2022.09.002_bib10","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1001\/archinte.168.8.847","article-title":"Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF","volume":"168","author":"Fonarow","year":"2008","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2022.09.002_bib11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","article-title":"Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis","volume":"35","author":"Damman","year":"2014","journal-title":"Eur Heart J"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib12","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2015-000324","article-title":"Prevalence and prognostic impact of kidney disease on heart failure patients","volume":"3","author":"L\u00f6fman","year":"2016","journal-title":"Open Heart"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib13","series-title":"USRDS Annual Data Report: Epidemiology of kidney disease in the United States. 2020","year":"2020"},{"issue":"4S","key":"10.1016\/j.mayocpiqo.2022.09.002_bib14","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105859","article-title":"Nonsteroidal mineralocorticoid receptor antagonism for cardiovascular and renal disorders - new perspectives for combination therapy","volume":"172","author":"Kolkhof","year":"2021","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib16","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1152\/physrev.00011.2014","article-title":"Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited","volume":"95","author":"Rossier","year":"2015","journal-title":"Physiol Rev"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib17","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/S0735-1097(01)01539-X","article-title":"Relationship between transcardiac extraction of aldosterone and left ventricular remodeling in patients with first acute myocardial infarction: extracting aldosterone through the heart promotes ventricular remodeling after acute myocardial infarction","volume":"38","author":"Hayashi","year":"2001","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib18","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1161\/01.CIR.103.1.72","article-title":"Aldosterone production is activated in failing ventricle in humans","volume":"103","author":"Mizuno","year":"2001","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib19","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/01.HYP.0000015905.27598.E9","article-title":"Aldosterone is produced from ventricles in patients with essential hypertension","volume":"39","author":"Yamamoto","year":"2002","journal-title":"Hypertension"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.tem.2012.09.004","article-title":"Aldosterone and cardiovascular disease: the heart of the matter","volume":"24","author":"He","year":"2013","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib21","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1152\/ajpendo.00100.2011","article-title":"Extra-adrenal glucocorticoids and mineralocorticoids: evidence for local synthesis, regulation, and function","volume":"301","author":"Taves","year":"2011","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib22","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: Toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib23","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.2215\/CJN.08580813","article-title":"Regulation of potassium homeostasis","volume":"10","author":"Palmer","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2022.09.002_bib24","doi-asserted-by":"crossref","first-page":"561","DOI":"10.34067\/KID.0006762021","article-title":"Extrarenal effects of aldosterone on potassium homeostasis","volume":"3","author":"Palmer","year":"2022","journal-title":"Kidney360"},{"issue":"7","key":"10.1016\/j.mayocpiqo.2022.09.002_bib25","article-title":"Hyperkalemia after initiating renin-angiotensin system blockade: the Stockholm Creatinine Measurements (SCREAM) project","volume":"6","author":"Bandak","year":"2017","journal-title":"J\u00a0Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib26","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/ki.1980.14","article-title":"Hyperkalemia and hyporeninemic hypoaldosteronism","volume":"17","author":"DeFronzo","year":"1980","journal-title":"Kidney Int"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib27","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","article-title":"Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine","volume":"42","author":"Agarwal","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib28","doi-asserted-by":"crossref","DOI":"10.1621\/nrs.05012","article-title":"The mineralocorticoid receptor: insights into its molecular and (patho)physiological biology","volume":"5","author":"Viengchareun","year":"2007","journal-title":"Nucl Recept Signal"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib29","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1038\/s41581-021-00490-8","article-title":"Mineralocorticoid receptor antagonists in diabetic kidney disease\u2014mechanistic and therapeutic effects","volume":"18","author":"Barrera-Chimal","year":"2022","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2022.09.002_bib30","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/ki.1978.114","article-title":"Role of aldosterone in the control of sodium excretion in patients with advanced chronic renal failure","volume":"14","author":"Berl","year":"1978","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib31","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/ki.1982.14","article-title":"Plasma aldosterone concentrations in chronic renal disease","volume":"21","author":"Hen\u00e9","year":"1982","journal-title":"Kidney Int"},{"issue":"1 Pt 2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib32","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1161\/01.HYP.33.1.232","article-title":"Role of aldosterone in renal vascular injury in stroke-prone hypertensive rats","volume":"33","author":"Rocha","year":"1999","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2022.09.002_bib33","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1210\/endo.141.10.7711","article-title":"Aldosterone: a mediator of myocardial necrosis and renal arteriopathy","volume":"141","author":"Rocha","year":"2000","journal-title":"Endocrinology"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib35","doi-asserted-by":"crossref","unstructured":"Zheng CM, Wang JY, Chen TT, et\u00a0al. Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population. Sci Rep. 2019;9(1):2694. Published correction appears in Sci Rep. 2020;10(1):6631.Pubmed Partial Author articletitle","DOI":"10.1038\/s41598-020-63162-w"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2022.09.002_bib36","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1038\/ncpneph0575","article-title":"The incidence and implications of aldosterone breakthrough","volume":"3","author":"Bomback","year":"2007","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib37","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nrneph.2009.228","article-title":"Aldosterone 'escape' vs 'breakthrough","volume":"6","author":"Schrier","year":"2010","journal-title":"Nat Rev Nephrol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2022.09.002_bib38","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1038\/hr.2013.74","article-title":"Effect of aldosterone breakthrough on albuminuria during treatment with a direct renin inhibitor and combined effect with a mineralocorticoid receptor antagonist","volume":"36","author":"Sato","year":"2013","journal-title":"Hypertens Res"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2022.09.002_bib39","first-page":"B4265","article-title":"The renin-angiotensin-aldosterone system and its blockade in diabetic nephropathy: main focus on the role of aldosterone","volume":"58","author":"Schjoedt","year":"2011","journal-title":"Dan Med Bull"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib40","doi-asserted-by":"crossref","unstructured":"Fried LF, Emanuele N, Zhang JH, et\u00a0al. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369(20):1892-1903. Published correction appears in N Engl J Med. 2014;158:A7255.","DOI":"10.1056\/NEJMoa1303154"},{"issue":"12","key":"10.1016\/j.mayocpiqo.2022.09.002_bib41","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","article-title":"Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study","volume":"54","author":"Imai","year":"2011","journal-title":"Diabetologia"},{"issue":"15","key":"10.1016\/j.mayocpiqo.2022.09.002_bib42","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","author":"Yusuf","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib43","doi-asserted-by":"crossref","unstructured":"Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet. 2007;370(9583):221-229. Published correction appears in Lancet. 2007;370(9598):1542.","DOI":"10.1016\/S0140-6736(07)61124-6"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib44","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/HJH.0b013e3280103a6b","article-title":"Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide","volume":"25","author":"Villamil","year":"2007","journal-title":"J\u00a0Hypertens"},{"issue":"23","key":"10.1016\/j.mayocpiqo.2022.09.002_bib45","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1056\/NEJMoa1208799","article-title":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes","volume":"367","author":"Parving","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib46","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/1479164117715854","article-title":"Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: a systematic review and meta-analysis of 13,395 patients","volume":"14","author":"Zheng","year":"2017","journal-title":"Diab Vasc Dis Res"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib47","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: Standards of medical care in diabetes-2022. Diabetes Care. 2022;45(suppl 1):S144-S174. Published correction appears in Diabetes Care. 2022;45(5):1296.","DOI":"10.2337\/dc22-er05"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib48","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","article-title":"30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development","volume":"234","author":"Kolkhof","year":"2017","journal-title":"J\u00a0Endocrinol"},{"issue":"31","key":"10.1016\/j.mayocpiqo.2022.09.002_bib49","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2022.09.002_bib52","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1001\/jama.1963.73700230005018","article-title":"Gynecomastia during therapy with spironolactone","volume":"184","author":"Mann","year":"1963","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib53","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2133.1988.tb02571.x","article-title":"Tolerance of spironolactone","volume":"118","author":"Hughes","year":"1988","journal-title":"Br J Dermatol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib54","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/eurjhf\/hfs061","article-title":"Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease","volume":"14","author":"Pitt","year":"2012","journal-title":"Eur J Heart Fail"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2022.09.002_bib55","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1124\/dmd.31.11.1448","article-title":"Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans","volume":"31","author":"Cook","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2022.09.002_bib56","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"B\u00e4rfacker","year":"2012","journal-title":"ChemMedChem"},{"issue":"11","key":"10.1016\/j.mayocpiqo.2022.09.002_bib57","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1124\/dmd.118.083337","article-title":"Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in\u00a0vivo and in\u00a0vitro","volume":"46","author":"Gerisch","year":"2018","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib58","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/cpdd.263","article-title":"Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment","volume":"5","author":"Heinig","year":"2016","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"36","key":"10.1016\/j.mayocpiqo.2022.09.002_bib59","doi-asserted-by":"crossref","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","article-title":"Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1","volume":"290","author":"Amazit","year":"2015","journal-title":"J\u00a0Biol Chem"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib60","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202002043RR","article-title":"Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells","volume":"35","author":"Le Billan","year":"2021","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"27","key":"10.1016\/j.mayocpiqo.2022.09.002_bib62","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2022.09.002_bib63","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","article-title":"Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone's antifibrotic activity","volume":"71","author":"Grune","year":"2018","journal-title":"Hypertension"},{"issue":"23","key":"10.1016\/j.mayocpiqo.2022.09.002_bib64","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.mayocpiqo.2022.09.002_bib65","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mayocpiqo.2022.09.002_bib66","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1111\/bph.15747","article-title":"Novel non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease","volume":"179","author":"Kintscher","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib67","first-page":"217","article-title":"Eplerenone (Inspra), a new aldosterone antagonist for the treatment of systemic hypertension and heart failure","volume":"17","author":"Craft","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2022.09.002_bib68","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","article-title":"Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension","volume":"15","author":"Weinberger","year":"2002","journal-title":"Am J Hypertens"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib69","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1210\/endo-97-1-52","article-title":"Antiandrogenic effect of spirolactones: mechanism of action","volume":"97","author":"Corvol","year":"1975","journal-title":"Endocrinology"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib70","doi-asserted-by":"crossref","unstructured":"Bramlage P, Swift SL, Thoenes M, Minguet J, Ferrero C, Schmieder RE. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease. Eur J Heart Fail. 2016;18(1):28-37. Published correction appears in Eur J Heart Fail. 2017;19(6):811.","DOI":"10.1002\/ejhf.444"},{"issue":"39","key":"10.1016\/j.mayocpiqo.2022.09.002_bib71","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A\u00a0new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib72","doi-asserted-by":"crossref","unstructured":"Pitt B, Remme W, Zannad F, et\u00a0al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348(14):1309-1321. Published correction appears in N Engl J Med. 2003;348(22):2271.","DOI":"10.1056\/NEJMoa030207"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib73","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1093\/ehjcvp\/pvw016","article-title":"Mineralocorticoid receptor antagonists in patients with heart failure: current experience and future perspectives","volume":"3","author":"Pitt","year":"2017","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"10","key":"10.1016\/j.mayocpiqo.2022.09.002_bib74","first-page":"CD007004","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib75","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"3","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib76","first-page":"CD007004","article-title":"Aldosterone antagonists for preventing the progression of chronic kidney disease","volume":"4","author":"Bolignano","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib77","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ejim.2013.11.007","article-title":"Mineralocorticoid receptor blockade in addition to angiotensin converting enzyme inhibitor or angiotensin II receptor blocker treatment: an emerging paradigm in diabetic nephropathy: a systematic review","volume":"25","author":"Mavrakanas","year":"2014","journal-title":"Eur J Intern Med"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib78","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","article-title":"Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis","volume":"17","author":"Currie","year":"2016","journal-title":"BMC Nephrol"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2022.09.002_bib79","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/jdi.12629","article-title":"Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy","volume":"8","author":"Sun","year":"2017","journal-title":"J\u00a0Diabetes Investig"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2022.09.002_bib80","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","article-title":"Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists","volume":"22","author":"Sueta","year":"2020","journal-title":"Curr Hypertens Rep"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib81","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1161\/HYPERTENSIONAHA.121.17073","article-title":"Effect of KBP-5074 on blood pressure in advanced chronic kidney disease: results of the BLOCK-CKD study","volume":"78","author":"Bakris","year":"2021","journal-title":"Hypertension"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib82","series-title":"Prescribing Information","year":"2021"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2022.09.002_bib83","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib84","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1161\/CIRCULATIONAHA.120.051898","article-title":"Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes","volume":"143","author":"Filippatos","year":"2021","journal-title":"Circulation"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib85","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1159\/000503712","article-title":"Design and baseline characteristics of the finerenone in reducing cardiovascular mortality and morbidity in diabetic kidney disease trial","volume":"50","author":"Ruilope","year":"2019","journal-title":"Am J Nephrol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib86","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","article-title":"A\u00a0randomized controlled study of finerenone vs. eplerenone in Japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease","volume":"80","author":"Sato","year":"2016","journal-title":"Circ J"},{"issue":"4","key":"10.1016\/j.mayocpiqo.2022.09.002_bib87","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","article-title":"A\u00a0randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy","volume":"31","author":"Katayama","year":"2017","journal-title":"J\u00a0Diabetes Complications"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib88","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","article-title":"Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes","volume":"78","author":"Filippatos","year":"2021","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib89","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","article-title":"Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial","volume":"145","author":"Filippatos","year":"2022","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib90","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/0014-2999(73)90232-X","article-title":"Cerebral uptake of a 3 H-labelled spirolactone compound in the dog","volume":"21","author":"Schmiedek","year":"1973","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib91","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.mce.2011.05.005","article-title":"Central regulation of blood pressure by the mineralocorticoid receptor","volume":"350","author":"Gomez-Sanchez","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"10.1016\/j.mayocpiqo.2022.09.002_bib92","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","article-title":"Nonsteroidal mineralocorticoid receptor antagonist finerenone protects\u00a0against acute kidney injury-mediated chronic kidney disease: role of oxidative stress","volume":"69","author":"Lattenist","year":"2017","journal-title":"Hypertension"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib93","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","article-title":"The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling","volume":"93","author":"Barrera-Chimal","year":"2018","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.mayocpiqo.2022.09.002_bib94","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1093\/ndt\/gfaa294","article-title":"Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone","volume":"37","author":"Agarwal","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib95","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1053\/j.ajkd.2021.02.324","article-title":"Finerenone-A new frontier in renin-angiotensin-aldosterone system inhibition in diabetic kidney disease","volume":"78","author":"Sridhar","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib96","doi-asserted-by":"crossref","unstructured":"Agarwal R, Filippatos G, Pitt B, et\u00a0al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43(6):474-484. Published correction appears in Eur Heart J. 2022;43(20):1989.","DOI":"10.1093\/eurheartj\/ehab777"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib97","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","article-title":"Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist","volume":"761","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib98","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","article-title":"CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats","volume":"769","author":"Arai","year":"2015","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2022.09.002_bib99","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","article-title":"Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial","volume":"14","author":"Ito","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib100","unstructured":"Kikkawa K, Shirata N, Takakuwa M, et al. MT-3995, a novel non-steroidal mineralocorticoid receptor antagonist, has pharmacological profiles differentiated from eplerenone and spironolactone. Presented at: ASN Kidney Week; October 31-Nov 5, 2017; New Orleans, LA."},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib101","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib102","first-page":"1","article-title":"Pharmacological profile of KBP-5074, a novel nonsteroidal mineralocorticoid receptor antagonist for the treatment of cardiorenal diseases","volume":"3","author":"Chow","year":"2017","journal-title":"J\u00a0Drug Res Dev"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2022.09.002_bib103","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/ejhf.1860","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre-specified subgroup with heart failure","volume":"22","author":"Rossignol","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"10.1016\/j.mayocpiqo.2022.09.002_bib104","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2215\/CJN.02150221","article-title":"The RALES legacy and finerenone use on CKD patients","volume":"16","author":"Moura-Neto","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib105","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mayocp.2019.05.019","article-title":"Potassium binders for hyperkalemia in chronic kidney disease-diet, renin-angiotensin-aldosterone system inhibitor therapy, and hemodialysis","volume":"95","author":"Palmer","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"10208","key":"10.1016\/j.mayocpiqo.2022.09.002_bib106","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(19)32135-X","article-title":"Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"394","author":"Agarwal","year":"2019","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.mayocpiqo.2022.09.002_bib107","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.mayocp.2020.06.014","article-title":"Clinical management of hyperkalemia","volume":"96","author":"Palmer","year":"2021","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib108","doi-asserted-by":"crossref","unstructured":"Whelton PK, Carey RM, Aronow WS, et\u00a0al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;71(19):e127-e248. Published correction appears in J Am Coll Cardiol. 2018;71(19):2275-2279.","DOI":"10.1161\/HYP.0000000000000076"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib109","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1053\/j.ajkd.2018.12.044","article-title":"Hypertension in CKD: core curriculum 2019","volume":"74","author":"Ku","year":"2019","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13098-019-0476-0","article-title":"Consensus recommendations for management of patients with type 2 diabetes mellitus and cardiovascular diseases","volume":"11","author":"Bashier","year":"2019","journal-title":"Diabetol Metab Syndr"},{"issue":"suppl. 1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib111","first-page":"S175","article-title":"American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes-2022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib112","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"issue":"2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib113","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10787-021-00797-9","article-title":"Anti-inflammatory potential of empagliflozin","volume":"29","author":"Pirklbauer","year":"2021","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib114","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s13300-015-0150-y","article-title":"Effect of the SGLT2 inhibitor dapagliflozin on potassium levels in patients with type 2 diabetes mellitus: a pooled analysis","volume":"7","author":"Yavin","year":"2016","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib115","doi-asserted-by":"crossref","unstructured":"Butler J, Usman MS, Khan MS, et\u00a0al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta-analysis. ESC Heart Fail. 2020;7(6):3298-3309. Published correction appears in ESC Heart Fail. 2021;8(3):2362.","DOI":"10.1002\/ehf2.13169"},{"issue":"39","key":"10.1016\/j.mayocpiqo.2022.09.002_bib116","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1093\/eurheartj\/ehz687","volume":"40","author":"Grant","year":"2019","journal-title":"Eur Heart J"},{"issue":"8","key":"10.1016\/j.mayocpiqo.2022.09.002_bib117","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1681\/ASN.2022020207","article-title":"Albuminuria-lowering effect of dapagliflozin, eplerenone, and their combination in patients with chronic kidney disease: a randomized crossover clinical trial","volume":"33","author":"Provenzano","year":"2022","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib118","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.ekir.2021.10.008","article-title":"Finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium-glucose cotransporter-2 inhibitor therapy","volume":"7","author":"Rossing","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"suppl 2","key":"10.1016\/j.mayocpiqo.2022.09.002_bib119","article-title":"Dapagliflozin reduces the risk of hyperkalaemia in patients with heart failure and reduced ejection fraction: a secondary analysis DAPA-HF","volume":"41","author":"Kristensen","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib120","unstructured":"Agarwal R, Wilson D, Joseph A, et al. Incidence and predictors of hyperkalemia in patients with CKD and T2D in the FIDELIO-DKD trial. Presented at: ISN World Congress of Nephrology; April 15-19, 2021: Virtual."},{"key":"10.1016\/j.mayocpiqo.2022.09.002_bib121","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.702326","article-title":"Neutral effects of combined treatment with GLP-1R agonist exenatide and MR antagonist potassium canrenoate on cardiac function in porcine and murine chronic heart failure models","volume":"12","author":"Demkes","year":"2021","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.mayocpiqo.2022.09.002_bib122","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/dom.14558","article-title":"Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: a subgroup analysis from the FIDELIO-DKD trial","volume":"24","author":"Rossing","year":"2022","journal-title":"Diabetes Obes Metab"}],"container-title":["Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454822000601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2542454822000601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T14:11:23Z","timestamp":1762870283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2542454822000601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":119,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S2542454822000601"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2022.09.002","relation":{},"ISSN":["2542-4548"],"issn-type":[{"value":"2542-4548","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evolution of Mineralocorticoid Receptor Antagonists in the Treatment of Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings: Innovations, Quality & Outcomes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocpiqo.2022.09.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc on behalf of Mayo Foundation for Medical Education and Research.","name":"copyright","label":"Copyright"}]}}